IN10018

Phase 3Small molecule

IInxMed (Shanghai) Co., Ltd.

IN10018 is one of 189 small molecule programs targeting Cervical Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

188

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical AdenocarcinomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Cervical AdenocarcinomaPhase 2

Active, not recruiting

AdenocarcinomaPhase 1

Active, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

IN10018

IInxMed (Shanghai) Co., Ltd.

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Imjudo

AstraZeneca

Preclinical

5 6

Vizimpro

Pfizer

Preclinical

4 7

Gilotrif

Boehringer Ingelheim

Preclinical

12 8

Ofev

Boehringer Ingelheim

Preclinical

7 9

Immunotherapy

Remeron

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Recruiting

Combination Therapy

NCT05994131

Q4 2026

Phase 2Recruiting

Cervical Adenocarcinoma

NCT06654011

Phase 2Recruiting

Ovarian Cancer

NCT06014528

Phase 1/2Not yet recruiting

Combination Therapy

NCT05982522

Q4 2027

Phase 1Recruiting

KRAS G12C Mutation

NCT06946927

Q3 2030

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT07174908

Clinical

Trials by Indication[1]

Combination Therapy3 trials

IN10018 Combination Therapy in Previously-treated Solid Tumors

Not yet recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT05982522·72 enrolled

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT06030258·120 enrolled

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT05994131·110 enrolled

Ovarian Cancer2 trials

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT05551507·150 enrolled

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 2·NCT06014528·168 enrolled

Solid Tumors1 trial

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Active, not recruiting·IInventisBio Co., Ltd·Phase 1/2·NCT05379946·92 enrolled

Pancreatic Cancer1 trial

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT05827796·70 enrolled

KRAS G12C Mutation1 trial

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

Recruiting·JJemincare·Phase 1·NCT06946927·72 enrolled

5 more indications

Cervical Adenocarcinoma1 trial

IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06654011·25 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT07441174·92 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 3·NCT07174908·400 enrolled

Adenocarcinoma1 trial

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Completed·IInxMed (Shanghai) Co., Ltd.·Phase 1·NCT05327231·33 enrolled

Metastatic Melanoma1 trial

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Completed·IInxMed (Shanghai) Co., Ltd.·Phase 1·NCT04109456·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for IN10018. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IN10018 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IN10018. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — InxMed (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInxMed (Shanghai) Co., Ltd.

IN10018

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q4 2027

Q3 2030

Trials by Indication[1]

Combination Therapy3 trials

Ovarian Cancer2 trials

Solid Tumors1 trial

Pancreatic Cancer1 trial

KRAS G12C Mutation1 trial

Cervical Adenocarcinoma1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Non-Small Cell Lung Cancer1 trial

Adenocarcinoma1 trial

Metastatic Melanoma1 trial

References

Drug Info

Quick Facts

Related News